Published in Oncol Rep on December 22, 2011
Ovarian cancer: involvement of the matrix metalloproteinases. Reproduction (2015) 0.88
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015) 0.85
Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol (2013) 0.83
The role of the tumor stroma in ovarian cancer. Front Oncol (2014) 0.81
Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer. Diagn Pathol (2016) 0.76
The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer (2015) 0.76
MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. J Ovarian Res (2016) 0.75
Multiple significance tests: the Bonferroni method. BMJ (1995) 23.46
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol (2002) 1.87
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis (1999) 1.40
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer (2005) 1.29
Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol (2000) 1.21
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol (2001) 1.16
Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10
MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol (1998) 1.09
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol (2006) 1.09
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog (2007) 0.99
Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol (2005) 0.98
Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer (2010) 0.95
Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol (2002) 0.95
Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol (2010) 0.94
Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol (2000) 0.94
Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol (2008) 0.92
Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer (2006) 0.92
Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol (2006) 0.91
Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med (2001) 0.90
Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol (2007) 0.89
Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol (2008) 0.89
The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS (2009) 0.88
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer (2001) 0.86
Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumour Biol (2004) 0.86
Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res (2005) 0.84
Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol (2003) 0.83
High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol (2006) 0.83
Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol (2000) 0.81
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol (2011) 2.35
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol (2005) 2.07
Laparoscopic sentinel lymph node procedure using a combination of patent blue and radioisotope in women with cervical carcinoma. Cancer (2003) 2.01
The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. Am J Obstet Gynecol (2012) 2.01
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol (2002) 1.81
Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol (2009) 1.77
Randomized trial of laparoscopically assisted versus open colorectal resection for endometriosis: morbidity, symptoms, quality of life, and fertility. Ann Surg (2010) 1.74
Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. Radiology (2004) 1.72
Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril (2008) 1.72
External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol (2008) 1.71
Quality of life after laparoscopic colorectal resection for endometriosis. Hum Reprod (2006) 1.66
Contralateral axillary sentinel lymph node drainage in breast cancer: a case report. J Surg Oncol (2004) 1.60
Use of the sentinel node procedure to stage endometrial cancer. Ann Surg Oncol (2008) 1.54
Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol (2009) 1.48
Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Am J Obstet Gynecol (2005) 1.45
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol (2007) 1.44
Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol (2010) 1.43
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg (2003) 1.40
A case-control study of polymorphic eruption of pregnancy. J Am Acad Dermatol (2007) 1.39
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol (2005) 1.33
Is planned vaginal delivery for breech presentation at term still an option? Results of an observational prospective survey in France and Belgium. Am J Obstet Gynecol (2006) 1.32
Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer (2010) 1.31
Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol (2011) 1.29
An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat (2005) 1.27
Maternal neoangiogenesis during pregnancy partly derives from fetal endothelial progenitor cells. Proc Natl Acad Sci U S A (2007) 1.27
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol (2009) 1.25
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer (2004) 1.22
Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology (2010) 1.19
Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol (2009) 1.18
Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem (2004) 1.16
Body mass index and outcome of tension-free vaginal tape. Eur Urol (2003) 1.16
Functional results and quality-of-life after bilateral sacrospinous ligament fixation for genital prolapse. Eur J Obstet Gynecol Reprod Biol (2006) 1.15
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14
Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and müllerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab (2008) 1.12
Dynamic contrast-enhanced magnetic resonance imaging: a useful tool for characterizing ovarian epithelial tumors. J Magn Reson Imaging (2008) 1.12
Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers. Hum Reprod (2009) 1.10
Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol (2010) 1.10
Outcome of laparoscopic colorectal resection for endometriosis. Curr Opin Obstet Gynecol (2007) 1.10
Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol (2010) 1.09
Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 1.09
How soon can I be proficient in embryo transfer? Lessons from the cumulative summation test for learning curve (LC-CUSUM). Hum Reprod (2009) 1.08
Breast cancer stroma frequently recruits fetal derived cells during pregnancy. Breast Cancer Res (2008) 1.07
Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer. J Surg Oncol (2005) 1.07
Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology (2008) 1.06
Pregnancy allows the transfer and differentiation of fetal lymphoid progenitors into functional T and B cells in mothers. J Immunol (2008) 1.05
Pregnancy outcomes after treatment for fibromyomata: uterine artery embolization versus laparoscopic myomectomy. Am J Obstet Gynecol (2004) 1.05
Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr (2008) 1.03
Anal fissure and thrombosed external hemorrhoids before and after delivery. Dis Colon Rectum (2002) 1.02
Axillary sentinel node involvement by breast cancer coexisting with B-cell follicular lymphoma in nonsentinel nodes. Breast J (2005) 1.02
Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer (2004) 1.02
Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol (2006) 1.01
Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique. Int J Gynecol Cancer (2011) 1.00
Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy. Gynecol Oncol (2004) 0.98
Ultrastaging of lymph node in uterine cancers. J Exp Clin Cancer Res (2010) 0.98
Treatment of genital prolapse by hammock using porcine skin collagen implant (Pelvicol). Urology (2005) 0.96
Pregnancy-associated breast cancers: do they differ from other breast cancers in young women? Breast (2012) 0.96
A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol (2012) 0.96
Increased fetal cell microchimerism in high grade breast carcinomas occurring during pregnancy. Int J Cancer (2009) 0.96
Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival. Ann Surg Oncol (2005) 0.96
Urinary complications after surgery for posterior deep infiltrating endometriosis are related to the extent of dissection and to uterosacral ligaments resection. J Minim Invasive Gynecol (2008) 0.96
Accuracy of magnetic resonance imaging and rectal endoscopic sonography for the prediction of location of deep pelvic endometriosis. Hum Reprod (2007) 0.95
CD34+ cells in maternal placental blood are mainly fetal in origin and express endothelial markers. Lab Invest (2009) 0.95
How to differentiate benign from malignant myometrial tumours using MR imaging. Eur Radiol (2013) 0.95
Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril (2005) 0.95
Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol (2010) 0.94
Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol (2005) 0.94
Laparoscopic radical hysterectomy for invasive cervical cancer: 8-year experience of a pilot study. Gynecol Oncol (2003) 0.93